BackTable Urology
Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay
Dr. Rana McKay
I think for people that have, that are undergoing radiation, there absolutely is a role for ADT and the duration and intensity varies dependent on the risk of the patient. And so in the context of intermediate risk disease, six months of a GnRH analog would be sufficient for patients with high risk disease, two years of therapy.
0
💬
0
Comments
Log in to comment.
There are no comments yet.